Scroll

Elevating the Future
of Cancer Care with
Alpha Theranostics.

ACCELERATE.EU is a project pioneering the development of novel radiotheranostic pairs featuring the alpha-emitting isotope astatine-211 (²¹¹At) to target aggressive cancers like pancreatic, breast, and brain cancer. By combining innovative therapies with a new generation of compact cyclotrons, the project aims to enhance cancer treatment outcomes and make these advanced therapies more accessible in clinical settings.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101173001. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.

Essential facts about the project driving the expansion
of Alpha therapy in Europe

17
Partners
9
countries
5
Years
16
M€ budget
100
Manpower
3
Industry
 partners
3
Unmet  
clinical needs
30+
Patients  
treated

With a strong
representation of
EU expertise in
nuclear medicine

This collaboration brings together 17 leading European institutions and companies across 9 countries, blending academic expertise with industrial innovation.

Complementary expertise across EU members

Resilient & strategic EU initiative to stand as a frontrunner in targeted alpha therapy

Flagship ecosystem setting the ground for a broader partner adoption and larger patient benefits

Dedicated alpha-cyclotron to
enable ²¹¹At production network

Clinical trials for unmet
clinical needs

Innovative co-clinical approach
to boost alpha theranostic uptake

Supply of 7 Ci of ²¹¹At
over 5 years

Early supply
Ligand & radiolabeling
Preclinical & co-clinical
Clinical trials
Production scale-up

Transversal collaboration: 5 axes of
innovation to accelerate targeted
alpha-therapy uptake across EU

The Accelerate.EU project is set to transform the landscape of cancer care by pioneering the development of novel radiotheranostic solutions to address unmet clinical needs. At the heart of this initiative is ²¹¹At, a highly promising alpha-emitting radioisotope with the potential to treat aggressive cancers such as triple-negative breast cancer, pancreatic cancer, and glioblastoma. The project will focus on developing and testing new therapeutic agents, ensuring a robust and sustainable infrastructure for ²¹¹At production and treatment.

Early supply

1.5 M€

Ligand &
radiolabeling

1.9 M€

Preclinical &
co-clinical

1.8 M€

Clinical trials

3.2 M€

Production
scale-up

7.6 M€

Early supply
Ligand & radiolabeling
Preclinical & co-clinical
Clinical trials
Production scale-up

Consolidated contributions
along five work packages

Transition from research production capacity to industrial supply chain

Cross sectorial partnership: industry, biotech, universities, hospitals, patient association,…

Accelerated translation from experimental to clinical implementation

Risk-mitigated breakthroughs for
severe unmet clinical needs

By integrating the entire value chain—from bench to bedside—Accelerate.EU aims to streamline the supply of ²¹¹At across Europe, ensuring that patients have timely access to this innovative treatment. The project will also explore co-clinical approaches, where clinical studies run in parallel with preclinical studies, enhancing the ability to identify patients who are most likely to benefit from ²¹¹At therapy

From
bench...

Pancreas
PDAC
I = 0.09 ‰SR = 9 %
NTR1TRL 2
1.8 M€
Preclinical
Breast
TNBC
I = 0.17 ‰SR = 12 %
FAPiTRL 3
3.2 M€
Co-clinical + Phase I
Brain
GBM
I = 0.04 ‰SR = 5 %
SubPTRL 4
1.2 M€
Phase I

to
bedside

Early supply
Ligand & radiolabeling
Preclinical & co-clinical
Clinical trials

IBA onboards all along ²¹¹At value
chain for a total 8.5M€ invest with
20% funding from EC

The Accelerate.EU project, a groundbreaking EUR 16 million initiative, has been officially launched with the ambitious goal of establishing a resilient and strategic European autonomy in alpha therapies. This five-year project aims to enhance patient access to cutting-edge cancer treatments by creating a complete value chain for the production and clinical application of the alpha-emitting isotope Astatine-211 (²¹¹At).

New cyclotron development

Dedicated to 211At production
Easy-integration for network deployment

Dedicated team

Upstream value positioning

Innovative industrial targetry process

Downstream value positioning

Updated chemistry module Proprietary purification module

A significant industry investment
in synergy with public research

The project has secured EUR 8 million in funding from the European Commission under the Innovative Health Initiative (IHI), matched by an equivalent in-kind contribution from industry partners.

In-kind

Industry contributors:

6.8 M€
0.7 M€
0.5 M€

8 M€

Funding

Funding from the European commission under the Innovatibe Health Initiative (IHI)

8 M€

Early supply
Ligand & radiolabeling
Preclinical & co-clinical
Clinical trials
Production scale-up

16 M€

A public-private co-leadership to
steer and pace collective efforts…

As the industry leader of the Accelerate.EU initiative, IBA will facilitate the development of a production network to enable greater access to targeted alpha therapy across the EU through the development of a new alpha-machine cyclotron as an in-kind contribution. IBA will also work in close collaboration with the Jules Bordet Institute, the academic and clinical Accelerate.EU coordinator, to manage the project.